Integral Health Asset Management’s Precision BioSciences DTIL Stock Holding History

Integral Health Asset Management’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,667	Closed	-$1.08M	–	73
2022 Q1	$1.08M	Buy	11,667 +5,834	+100%	+$793K	0.28%	63
2021 Q4	$1.29M	Buy	5,833 +1,666	+40%	+$465K	0.36%	60
2021 Q3	$1.44M	Sell	4,167 -1,666	-29%	-$565K	0.41%	60
2021 Q2	$2.19M	Buy	+5,833	New	+$1.75M	0.6%	49
2021 Q1	–	Sell	-4,667	Closed	-$1.17M	–	76
2020 Q4	$1.17M	Sell	4,667 -5,333	-53%	-$1.31M	0.35%	55
2020 Q3	$1.85M	Buy	+10,000	New	+$1.99M	0.57%	59
2020 Q1	–	Sell	-1,667	Closed	-$695K	–	61
2019 Q4	$695K	Buy	+1,667	New	+$524K	0.27%	50

Other funds holding DTIL

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Integral Health Asset Management's DTIL Position: Q2 2022 in Review

Integral Health Asset Management sold out of Precision BioSciences (DTIL) in Q2 2022, closing a stake of 11,667 shares — an estimated $1.08M sold.

Integral Health Asset Management first reported a position in DTIL in Q4 2019 and held it in 7 quarters. The position peaked at $2.19M in Q2 2021. 119 funds tracked by Wall St. Rank hold DTIL as of Q2 2022.

Integral Health Asset Management reported no remaining Precision BioSciences position as of Q2 2022 after selling out during the quarter.
Integral Health Asset Management sold 11,667 Precision BioSciences shares in Q2 2022, an estimated $1.08M.
Integral Health Asset Management first reported a position in Precision BioSciences in Q4 2019 and held it in 7 quarters.
Integral Health Asset Management's Precision BioSciences position peaked at $2.19M in Q2 2021.
119 funds tracked by Wall St. Rank held Precision BioSciences as of Q2 2022.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.